The Company has stock-based compensation plans approved by its shareholders under which it grants stock options, restricted stock awards, restricted stock units and deferred stock units to officers, directors and key employees. Stock-based compensation expense was reported as follows in the condensed consolidated statements of operations:

	Three Months Ended				Six Months Ended
	March 31,				March 31,
(In thousands)	2022		2021		2022		2021
Product costs	$	78	$	32	$	108	$	69
Research and development		296		305		731		589
Selling, general and administrative		1,345		1,092		2,560		2,204
Total	$	1,719	$	1,429	$	3,399	$	2,862

As of March 31, 2022, approximately $12.8 million of total unrecognized compensation costs related to non-vested awards is expected to be recognized over a weighted average period of approximately 2.5 years.

The Company awards stock options to officers, directors and key employees and uses the Black-Scholes option pricing model to determine the fair value of stock options as of the date of each grant. Stock option grant activity was as follows:

	Six Months Ended March 31,
	2022		2021
Stock option grant activity:
Stock options granted		283,000		234,000
Weighted average grant date fair value	$	16.36	$	13.86
Weighted average exercise price	$	43.72	$	38.65

During the six months ended March 31, 2022 and 2021, the Company awarded 83,000 and 65,000 restricted stock shares, respectively, to certain key employees and officers with a weighted average grant date fair value per share of $43.87 and $37.48, respectively. Restricted Stock is valued based on the market value of the shares as of the date of grant.

During each of the six months ended March 31, 2022 and 2021, the Company awarded 14,000 and 12,000 restricted stock units, respectively, (“RSUs”) to directors and to key employees in foreign jurisdictions with a weighted average grant date fair value per unit of $42.79 and $45.13, respectively. RSUs are valued based on the market value of the shares as of the date of grant.

Our U.S. employees are eligible to participate in the amended 1999 Employee Stock Purchase Plan (“ESPP”) approved by our shareholders. During the six months ended March 31, 2022 and 2021, 10,000 and 8,000 shares were issued under the ESPP, respectively.